Please check your internet connection and try again.
This information pertains to a combination product of **daidzein**, **genistein**, and **palmitoylethanolamide (PEA)**.
## Overview
Daidzein and genistein are isoflavones found in soy, often referred to as phytoestrogens. Palmitoylethanolamide (PEA) is an endogenous fatty acid amide with proposed anti-inflammatory and analgesic properties. This combination is typically used as a dietary supplement.
## Primary Indications
This combination is not FDA-approved for any specific medical condition. It is commonly marketed for:
* Pain management, particularly neuropathic pain.
* Inflammatory conditions.
* Menopausal symptom relief.
## Adult Dosing
Dosing varies widely as this is a dietary supplement. Common reported doses for the combination include:
* Daidzein: 10-50 mg per day.
* Genistein: 10-50 mg per day.
* Palmitoylethanolamide (PEA): 300-1200 mg per day, sometimes divided into 2-3 doses.
Specific product formulations and recommended dosages should be followed.
## Pediatric Dosing
There is insufficient evidence to establish pediatric dosing for this combination. Its use in children is generally not recommended without specific medical guidance and evidence.
## Dose Adjustments
No specific dose adjustments are established for hepatic or renal impairment due to its status as a dietary supplement. However, caution is advised in patients with significant organ dysfunction.
## Contraindications
* Known hypersensitivity to any component of the product.
* Pregnancy and breastfeeding (due to limited safety data and potential hormonal effects).
* Patients with hormone-sensitive cancers (e.g., breast, ovarian, uterine) should exercise caution due to the phytoestrogenic nature of daidzein and genistein.
## Adverse Effects
Adverse effects are generally mild and may include:
* Gastrointestinal upset (nausea, diarrhea, abdominal pain).
* Headache.
* Allergic reactions.
* Potential hormonal effects (e.g., menstrual irregularities) with high doses or prolonged use of isoflavones.
## Key Drug Interactions
* **Hormone Replacement Therapy (HRT) and Oral Contraceptives:** Potential for additive effects or interactions due to phytoestrogenic activity.
* **Tamoxifen:** Phytoestrogens may interact with tamoxifen, potentially affecting its efficacy.
* **Warfarin:** High doses of soy isoflavones have been reported to affect INR. Caution is advised.
## Monitoring
* Monitor for gastrointestinal tolerance and any signs of allergic reaction.
* For patients with hormone-sensitive conditions or on hormone therapy, monitor for relevant clinical signs.
* In patients on warfarin, monitor INR closely if significant amounts are consumed.
## Clinical Pearls
* The efficacy and safety of this combination product are not well-established by rigorous clinical trials.
* Individual responses can vary significantly.
* Daidzein and genistein are poorly absorbed and subject to significant first-pass metabolism; gut microbiota play a role in their conversion to active metabolites.
* PEA's mechanism is thought to involve activation of the TRPV1 receptor and interaction with the endocannabinoid system.
***
*Disclaimer: This information is intended for educational purposes and does not substitute for professional medical advice. Always consult with a qualified healthcare provider and refer to the most current prescribing information or product monograph before making any decisions related to medication use.*
